Structure Therapeutics(US:GPCR)2025-12-08 13:30Aleniglipron Efficacy - In the Phase 2b ACCESS trial, Aleniglipron achieved placebo-adjusted mean weight loss of 82% at 45 mg, 98% at 90 mg, and 113% at 120 mg at 36 weeks[41] - Exploratory ACCESS II study showed placebo-adjusted mean weight loss at 36 weeks of 141% at 120 mg, 144% at 180 mg, and 153% at 240 mg[72] - ACCESS Open Label Extension (OLE) study indicated that weight loss continues to increase in all arms through Week 44, with no evidence of a weight loss plateau[50] Aleniglipron Tolerability and Safety - Phase 2b ACCESS trial showed an overall 104% AE-related treatment discontinuation rate, with GI-related AEs consistent with the GLP-1RA class[41] - In the Exploratory ACCESS II trial, participants who achieved re-randomization experienced no AE-related treatment discontinuations up to the 240 mg dose at week 36[72] - Body Composition study showed improved tolerability with a lower 25 mg starting dose, with no treatment discontinuations due to AEs after a median treatment of approximately 10 weeks[83] - Across all studies with over 500 participants treated up to 44 weeks, there were no events of drug-induced liver injury, off-target safety signals, or QTc prolongation[96] Market Opportunity and Scalability - The overweight and obesity market includes over 800 million people worldwide, with projections of 15 billion people by 2030[14] - The total addressable market for obesity treatments is estimated to be over $100 billion[14] - Oral small molecules like Aleniglipron can scale to meet the needs of the global obesity patient population, offering potential advantages in accessibility and cost compared to injectable peptides[12, 15]